Healthcare Industry News: HSMN NewsFeed
News Release - August 10, 2017
Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in CanadaMylan now offers generic alternatives to TruvadaŽ, AtriplaŽ and VireadŽ to patients in Canada1
HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today announced the launch in Canada of three generic products indicated in the treatment of HIV for certain patients. One of the products is Mylan-Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg, a generic alternative to TruvadaŽ.
Mylan received final approval from Health Canada for this product and for Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to AtriplaŽ; and Mylan-Tenofovir Disoproxil 300 mg, a generic alternative to VireadŽ.
Mylan's Chief Commercial Officer Tony Mauro said, "Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS and other diseases around the world, and today marks another milestone in those efforts. More than 40% of people worldwide being treated for HIV/AIDS with an antiretroviral depend on a Mylan product every day, and we're proud to further expand access to such medicines in Canada."
Approximately 37 million people globally are living with HIV/AIDS today. As a champion for access, Mylan has invested $250 million in expanding its antiretroviral (ARV) production capacity, enabling the company to produce 4 billion ARV tablets and capsules every year.
Mylan-Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600 mg, 200 mg, and 300 mg is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
Mylan-Tenofovir Disoproxil 300 mg is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 12 years of age and older and the treatment of chronic hepatitis B infection in adults.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com or Mylan.ca.
1 TruvadaŽ and VireadŽ are registered trademarks of Gilead Sciences, Inc. or its related companies. AtriplaŽ is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus(R) Patents
Mylan and Aspen Announce Launch of Generic Busulfex(R) Injection
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease